SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, Northern Ireland BT52 1SA, UK.
Curr Opin Pharmacol. 2013 Dec;13(6):989-95. doi: 10.1016/j.coph.2013.09.009. Epub 2013 Sep 21.
The utilisation of gastrointestinal-derived hormones as treatment options for obesity-diabetes has been well publicised. This has been fuelled by the synthesis of longer-acting peptide forms and beneficial altered secretion of gut hormones following certain gastric bypass surgeries. The aim of this review is to highlight the potential of glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), cholecystokinin (CCK) and oxyntomodulin (OXM) as treatments for obesity-diabetes. To date, long-acting GLP-1 receptor mimetics have achieved clinical utility for diabetes. GIP, CCK and OXM molecules appear to offer promising new classes of drugs. Furthermore, recent observations suggest significant potential for concurrent modulation of numerous receptor sub-families in the treatment of obesity-diabetes. Thus, gut hormones offer an expanding family of druggable targets for obesity-diabetes.
胃肠道来源的激素被广泛用作肥胖-糖尿病的治疗选择。这是由于合成了作用时间更长的肽形式，以及某些胃旁路手术后胃肠道激素的有益改变分泌。本综述的目的是强调葡萄糖依赖性胰岛素释放肽（GIP）、胰高血糖素样肽-1（GLP-1）、胆囊收缩素（CCK）和胰高血糖素样肽-2（OXM）作为肥胖-糖尿病治疗的潜力。迄今为止，长效 GLP-1 受体激动剂已在糖尿病治疗中获得临床应用。GIP、CCK 和 OXM 分子似乎提供了有前途的新药类。此外，最近的观察结果表明，在肥胖-糖尿病的治疗中，同时调节多种受体亚家族具有显著的潜力。因此，胃肠道激素为肥胖-糖尿病提供了一个不断扩大的可药物治疗靶点家族。
